Envestnet Asset Management Inc. Boosts Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Envestnet Asset Management Inc. increased its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 13.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,136,338 shares of the pharmaceutical company's stock after acquiring an additional 247,966 shares during the period. Envestnet Asset Management Inc. owned approximately 0.10% of GSK worth $82,762,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in GSK. Hexagon Capital Partners LLC raised its holdings in GSK by 8.0% during the 1st quarter. Hexagon Capital Partners LLC now owns 7,839 shares of the pharmaceutical company's stock valued at $304,000 after buying an additional 578 shares during the period. Concurrent Investment Advisors LLC increased its position in GSK by 28.3% during the first quarter. Concurrent Investment Advisors LLC now owns 16,857 shares of the pharmaceutical company's stock valued at $653,000 after acquiring an additional 3,719 shares during the last quarter. VAUGHAN & Co SECURITIES INC. raised its stake in shares of GSK by 34.6% in the first quarter. VAUGHAN & Co SECURITIES INC. now owns 18,708 shares of the pharmaceutical company's stock valued at $725,000 after acquiring an additional 4,805 shares during the period. HM Payson & Co. lifted its holdings in shares of GSK by 79.7% in the 1st quarter. HM Payson & Co. now owns 1,308 shares of the pharmaceutical company's stock worth $51,000 after acquiring an additional 580 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of GSK by 8.0% during the 1st quarter. Bank of New York Mellon Corp now owns 1,051,637 shares of the pharmaceutical company's stock worth $40,740,000 after purchasing an additional 77,586 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Stock Down 3.3%

Shares of GSK stock traded down $1.29 during mid-day trading on Friday, hitting $38.29. The stock had a trading volume of 6,299,600 shares, compared to its average volume of 4,982,521. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. The firm's 50-day moving average is $38.99 and its two-hundred day moving average is $37.23. The firm has a market capitalization of $78.39 billion, a P/E ratio of 9.70, a price-to-earnings-growth ratio of 1.59 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter last year, the firm posted $0.43 EPS. The company's revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were issued a dividend of $0.4216 per share. The ex-dividend date was Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.40%. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 88.14%.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Hold" and an average target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.